ライフサイエンスコーパス: respiratory tract infection

1 ERS) coronavirus causes a highly fatal lower-respiratory tract infection.

2 ve ability increase risk of dying from lower respiratory tract infection.

3 n cognitive ability and mortality from lower respiratory tract infection.

4 at resulted in two bacteremias and one lower respiratory tract infection.

5 vg+) phase that are necessary for successful respiratory tract infection.

6 on following a primary diagnosis of an upper respiratory tract infection.

7 rs), 414 (47%) were women, and 379 (43%) had respiratory tract infection.

8 for Haemophilus colonization and subsequent respiratory tract infection.

9 ial virus (HRSV) is a major cause of serious respiratory tract infection.

10 clinical presentation was frequently a mild respiratory tract infection.

11 dverse events were nasopharyngitis and upper respiratory tract infection.

12 ommon adverse events were headache and upper respiratory tract infection.

13 actor for the development of recurrent upper respiratory tract infections.

14 cept were injection-site reactions and upper respiratory tract infections.

15 nt of adults with bronchiectasis and chronic respiratory tract infections.

16 They often precede serious lower respiratory tract infections.

17 Numerous viruses can cause upper respiratory tract infections.

18 a exacerbations, and hospital attendance for respiratory tract infections.

19 escribing of antibiotics for childhood upper respiratory tract infections.

20 ide and represent the leading cause of upper respiratory tract infections.

21 nriched in clinical isolates associated with respiratory tract infections.

22 the appropriate use of antibiotics for acute respiratory tract infections.

23 rum antibiotics for most children with acute respiratory tract infections.

24 n children for the prevention of viral upper respiratory tract infections.

25 ae (NTHI) is the causative agent of multiple respiratory tract infections.

26 tion did not reduce overall wintertime upper respiratory tract infections.

27 ospitalized patients <2 years old with lower respiratory tract infections.

28 gic association in persons with severe lower respiratory tract infections.

29 t common indications were skin disorders and respiratory tract infections.

30 in D levels and a higher risk of viral upper respiratory tract infections.

31 ts frequently present to doctors with severe respiratory tract infections.

32 sitive and culture-negative sepsis and lower respiratory tract infections.

33 f future hospital admission in children with respiratory tract infections.

34 appropriate antibiotic prescribing for acute respiratory tract infections.

35 enza virus (PIV) is a leading cause of lower respiratory tract infections.

36 articular concern in the management of lower respiratory tract infections.

37 piratory syncytial virus (RSV)-induced lower respiratory tract infections.

38 method for detection of pathogens from lower respiratory tract infections.

39 ult patients with bronchiectasis and chronic respiratory tract infections.

40 in patients with bronchiectasis and chronic respiratory tract infections.

41 a (13 [12%]), headache (11 [10%]), and upper respiratory tract infection (11 [10%]).

42 dverse events in all groups were viral upper respiratory tract infection (14-16%) and worsening asthm

43 ction (19 [7%] vs 11 [4%] vs 13 [5%]), upper respiratory tract infection (15 [5%] vs 15 [5%] vs 11 [4

44 on (343 [45%] infections), followed by lower respiratory tract infections (171 [22%]), gastrointestin

45 two studies, 1 681 020 events) and for lower respiratory tract infections (-18.48% [-32.79 to -4.17];

46 s), and rates of hospital attendance for all respiratory tract infections (-3.45% [-4.64 to -2.25]; t

47 h dupilumab compared with placebo were upper respiratory tract infections (33-41% vs 35%) and injecti

48 haryngitis (30 [11%] vs 15 [11%]), and upper respiratory tract infection (35 [12%] vs ten [7%]).

49 The most common adverse events were upper respiratory tract infection (36 [10%] patients) and head

50 rse events included fatigue (62%), and upper respiratory tract infection (42%), infusion reactions (4

51 fections (54 [19%] of 278 patients had upper respiratory tract infections; 42 [15%] had bronchitis, 3

52 re infusion reactions (56 [38%] vs 0), upper respiratory tract infections (43 [28%] vs 26 [17%]), and

53 revalent ARI syndromes included: viral upper respiratory tract infection (47%), pharyngitis (18%), an

54 te ratio, 0.85; 95% CI, 0.79 to 0.91), upper respiratory tract infections (4893 vs. 5763 episodes; in

55 confirmed RSV ARTI (includes upper and lower respiratory tract infections), 500 without and 50 with c

56 , headache (57 [15%] vs 46 [12%]), and upper respiratory tract infection (51 [13%] vs 30 [8%]).

57 ost common adverse events overall were upper respiratory tract infection (51 [9%] of 581 patients rec

58 ts were fatigue (25%), headache (13%), upper respiratory tract infection (8%), and arthralgia (8%).

59 Acute respiratory tract infections account for the majority of

60 5.2%]; placebo, 89 events [5.0%]), and upper respiratory tract infection (aclidinium, 86 events [4.8%

61 c-inappropriate diagnoses (nonspecific upper respiratory tract infections, acute bronchitis, and infl

62 , 2.75; 95% CI, 2.03 to 3.73), current upper respiratory tract infection (adjusted odds ratio, 1.35;

63 ong the most important causes of acute lower respiratory tract infection (ALRI) in young children.

64 t hospitalizations for all-cause acute lower respiratory tract infection (ALRI).

65 dren worldwide, commonly through acute lower respiratory tract infections (ALRI).

66 al virus (RSV) is the leading cause of lower respiratory tract infection among infants and young chil

67 yncytial virus is the leading cause of lower respiratory tract infection among infants.

68 ate with the incidence and severity of acute respiratory tract infection and childhood asthma develop

69 d high risk of future hospital admission for respiratory tract infection and could be used to reduce

70 180 days to assess outcomes related to lower respiratory tract infection and for 364 days to assess s

71 g viral pathogen associated with acute lower respiratory tract infection and hospitalization in child

72 It is a major cause of acute lower respiratory tract infection and is associated with signi

73 y elective CS had an increased risk of lower respiratory tract infection and juvenile idiopathic arth

74 ic patterns of AWaRe antibiotic use in lower respiratory tract infection and neonatal sepsis were obs

75 anisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE

76 months and 12 years diagnosed with an acute respiratory tract infection and prescribed an oral antib

77 er fashion as regards risk factors for lower respiratory tract infection and there is evidence that t

78 three common viruses implicated in seasonal respiratory tract infections and are a major cause of mo

79 general nontuberculosis morbidity, including respiratory tract infections and atopic diseases.

80 nt siblings presenting with recurrent severe respiratory tract infections and bronchiectasis.

81 tions, events that are often associated with respiratory tract infections and cold symptoms.

82 Bacterial respiratory tract infections and exacerbations of chroni

83 esent in the nasal mucosa during acute viral respiratory tract infections and further characterize th

84 cytial virus (RSV) is a major cause of lower respiratory tract infections and hospital visits during

85 us (RSV) is the leading cause of acute lower respiratory tract infections and hospitalizations in inf

86 ewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than p

87 teroid-insensitive asthma is associated with respiratory tract infections and noneosinophilic endotyp

88 , influenza, and respiratory syncytial virus respiratory tract infections and ovalbumin-induced, seve

89 um antibiotics and those admitted with lower respiratory tract infections and skin and soft tissue in

90 um antibiotics and those admitted with lower respiratory tract infections and skin and soft tissue in

91 ietary supplements, primarily to treat upper respiratory tract infections and to support immune funct

92 which were nasopharyngitis, influenza, upper respiratory tract infection, and headache.

93 verse events were injection-site pain, upper respiratory tract infection, and nausea.

94 %]), febrile neutropenia (five [10%]), lower respiratory tract infection, and pneumonia (each three [

95 iratory tract illnesses, time to first upper respiratory tract infection, and serum 25-hydroxyvitamin

96 d placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF; and t

97 nd susceptibility to allergic sensitization, respiratory tract infections, and asthma.

98 r respiratory tract infections, severe lower respiratory tract infections, and exacerbations of under

99 isodes of troublesome lung symptoms, asthma, respiratory tract infections, and neonatal airway immuno

100 Infusion-related reactions, upper respiratory tract infections, and oral herpes infections

101 tobacco smoke, controller medication, upper respiratory tract infections, and seasonality.

102 Viral respiratory tract infections are associated with asthma

103 Respiratory tract infections are frequent causes of hosp

104 Respiratory tract infections are often viral and but are

105 Respiratory tract infections are one of the leading caus

106 Viral respiratory tract infections are the main causative agen

107 Viral respiratory tract infections are the most common human a

108 Although non-CAAP lower respiratory tract infections are usually not considered

109 y-confirmed antibiotic-resistant urinary and respiratory-tract infections are more likely to experien

110 Acute respiratory tract infections (ARI) constitute a substant

111 s to identify biomarkers of severe RSV acute respiratory tract infection (ARTI) in infants.

112 elines on antibiotic prescriptions for acute respiratory tract infection (ARTI) in PEDs.

113 Acute respiratory tract infection (ARTI) is the most common re

114 cohort to obtain incidence data on RSV acute respiratory tract infection (ARTI).

115 t support use of systemic steroids for acute respiratory tract infections (ARTIs), but such practice

116 didates were efficacious in preventing lower respiratory tract infection as well as in reducing the n

117 used Bordetella pertussis, a common neonatal respiratory tract infection, as a proof of concept to in

118 Asthma-, allergy-, and respiratory tract infection-associated phenotypes (inclu

119 and the secondary end points included lower respiratory tract infections, asthma exacerbations, ecze

120 riate antibiotic prescribing for acute upper respiratory tract infections (AURIs) requires a better u

121 e number of laboratory-confirmed viral upper respiratory tract infections based on parent-collected n

122 Among children with acute respiratory tract infections, broad-spectrum antibiotics

123 Dementia increases the risk of lower respiratory tract infection, but it is unclear whether r

124 Early-life wheezing-associated respiratory tract infection by rhinovirus (RV) is a risk

125 While most viral respiratory tract infections can be diagnosed clinically

126 ntification of the causative agents of lower respiratory tract infections can promote better patient

127 Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coro

128 inflammation is a critical feature of lower respiratory tract infections caused by viruses such as r

129 ied a child with life-threatening, recurrent respiratory tract infections, caused by viruses includin

130 , stinging insects, fungi, pollutants, viral respiratory tract infections, climate change, and microb

131 60 yr) patients in health and during a lower respiratory tract infection, community-acquired pneumoni

132 Lower respiratory tract infection contributed to 174 (57%) of

133 me comprising a range of potentially serious respiratory tract infections, contributes to mortality i

134 5%] had bronchitis, 34 [12%] had viral upper respiratory tract infections), cough (34 [12%]), and dia

135 The most frequent AEs were fatigue, upper respiratory tract infection, cough, and dyspnea.

136 ice with TP73 deficiency suffer from chronic respiratory tract infections due to profound defects in

137 strongest manifest increased risk for severe respiratory tract infections during infancy and subseque

138 9% women) for antibiotic-inappropriate acute respiratory tract infections during the baseline period

139 ation study and subsequent symptoms of lower respiratory tract infections during the first year of li

140 pyrexia (eight [73%] of 11 patients), upper respiratory tract infection (eight [73%]), craniosynosto

141 HBoV1 is pathogenic to humans, causing acute respiratory tract infections, especially in young childr

142 lated from nasal lavage fluid during a viral respiratory tract infection expressed CysLTR1.

143 Mortality from lower respiratory tract infection fell as cognitive ability in

144 eight [8%] patients in each group) and upper respiratory tract infections (five [5%] patients in each

145 Virus-associated febrile lower respiratory tract infections (fLRIs) during infancy have

146 Lower respiratory tract infections from respiratory syncytial

147 Adverse events were manageable and included respiratory tract infections, gastrointestinal symptoms,

148 st frequently reported on-treatment AEs were respiratory tract infection, headache, bronchitis, and a

149 ween neonatal interferon responses and lower respiratory tract infection history during infancy, whee

150 ] women), clinical presentation was an upper respiratory tract infection in 12 (67%), and viral shedd

151 ects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma.

152 ruses (RVs) are a major cause of symptomatic respiratory tract infection in all age groups.

153 Parainfluenza virus (PIV) is a cause of respiratory tract infection in children and the immunoco

154 rus (hMPV) is a leading cause of viral lower respiratory tract infection in children.

155 ocavirus (HBoV) 1 can cause life-threatening respiratory tract infection in children.

156 d, although hMPV is a leading cause of lower respiratory tract infection in children.

157 b for the prevention of RSV-associated lower respiratory tract infection in healthy infants who had b

158 re present during symptoms of an acute viral respiratory tract infection in human subjects.

159 ion is a leading cause of severe acute lower respiratory tract infection in infants and children worl

160 RSV and hMPV are the leading causes of acute respiratory tract infection in infants and children.

161 virus (RSV) is a significant cause of lower respiratory tract infection in infants and elderly.

162 the most prevalent worldwide cause of severe respiratory tract infection in infants and young childre

163 l virus (RSV) is the leading cause of severe respiratory tract infection in infants and young childre

164 RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of

165 irus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exist

166 syncytial virus (RSV) is a leading cause of respiratory tract infection in infants, causing signific

167 rus (hRSV) is a leading cause of acute lower respiratory tract infection in infants, elderly and immu

168 (RSV) is the dominant cause of severe lower respiratory tract infection in infants, with the most se

169 us (RSV) is the most frequent cause of lower respiratory tract infection in infants.

170 efficiently inhibits established acute lower respiratory tract infection in the animals, even when tr

171 irmed COVID-19 adults with symptoms of lower respiratory tract infection in the emergency department

172 the pitavastatin group (n=12, 10%) and upper respiratory tract infection in the pravastatin group (n=

173 tial virus (RSV) is a leading cause of lower respiratory tract infection in young children worldwide.

174 cytial virus is a major cause of acute lower respiratory tract infection in young children, immunocom

175 -level proportion of prescriptions for upper respiratory tract infections in 2-14-year-old outpatient

176 cause of acute otitis media in children and respiratory tract infections in adults with chronic obst

177 RSV) is the leading etiologic agent of lower respiratory tract infections in children, but no license

178 rrow-spectrum antibiotic treatment for acute respiratory tract infections in children.

179 (hRSV) is the leading cause of severe lower respiratory tract infections in children.

180 Coronaviruses cause respiratory tract infections in humans and outbreaks of

181 nts.IMPORTANCE Influenza viruses cause upper respiratory tract infections in humans.

182 served in vivo and the occurrence of chronic respiratory tract infections in immunocompromised hosts.

183 he most common viruses associated with acute respiratory tract infections in infancy.

184 al virus (RSV) is the leading cause of lower respiratory tract infections in infants, a safe and effe

185 (RSV) is a major cause of severe acute lower respiratory tract infections in infants.

186 yncytial virus (RSV) is the primary cause of respiratory tract infections in infants; however, curren

187 al virus (RSV) is the leading cause of lower respiratory tract infections in the very young.

188 biotic use in patients with non-severe acute respiratory tract infections in Vietnam.

189 RSV is a major cause of serious lower respiratory tract infections in young children and cause

190 HBoV1 causes acute respiratory tract infections in young children and has a

191 e of the significant pathogens causing acute respiratory tract infections in young children worldwide

192 emerging respiratory virus that causes lower respiratory tract infections in young children worldwide

193 rus of the Parvoviridae family, causes acute respiratory tract infections in young children.

194 oV1) is a human parvovirus that causes acute respiratory tract infections in young children.

195 BoV1) is pathogenic to humans, causing acute respiratory tract infections in young children.

196 on reduces the incidence of wintertime upper respiratory tract infections in young children.

197 1 (HBoV1), a human parvovirus, causes lower respiratory tract infections in young children.

198 ytial virus (RSV) is the main cause of lower respiratory tract infections in young children.

199 a major causative agent of upper- and lower-respiratory-tract infections in infants, the elderly, an

200 en and is the leading cause of serious lower-respiratory-tract infections in young children.

201 ild diarrhea (in 52% of the patients), upper respiratory tract infection (in 48%), nausea (in 47%), a

202 Common grade 1-2 toxicities included upper respiratory tract infections (in 28 [57%] of 49 patients

203 of the respiratory tract during viral upper respiratory tract infection, in addition to the relation

204 Multiplex tests for respiratory tract infections include up to 20 targets fo

205 risk of respiratory morbidity from recurrent respiratory tract infections including those from respir

206 Lower respiratory tract infections, including hospital-acquire

207 Viral respiratory tract infections increase the risk of develo

208 thelial secretome participating in RSV lower respiratory tract infection-induced airway remodeling.

209 DARA-MD 1200 mg were thrombocytopenia, upper respiratory tract infection, insomnia, and decreased app

210 s pneumoniae, the transition to severe lower respiratory tract infection is associated with an increa

211 Acute lower respiratory tract infection is common and often treated

212 Respiratory syncytial virus (RSV) lower respiratory tract infection is implicated in asthma deve

213 g for viruses in children who present with a respiratory tract infection is to differentiate between

214 Inappropriate antibiotic use for acute respiratory tract infections is common in primary health

215 ad-spectrum antibiotic prescribing for acute respiratory tract infections is increasing.

216 body deficiencies (PADs) experience frequent respiratory tract infections, leading to chronic pulmona

217 nical trial of the FDA-cleared Unyvero lower respiratory tract infection (LRTI) application (Curetis)

218 Lower respiratory tract infection (LRTI) commonly causes hospi

219 ith respiratory failure (RF) and fatal lower respiratory tract infection (LRTI) in premature children

220 evious pulmonary tuberculosis (PTB) or lower respiratory tract infection (LRTI) was significantly ass

221 iratory tract infection (URTI) without lower respiratory tract infection (LRTI), URTI progressing to

222 common reason for hospitalization was lower respiratory tract infection (LRTI).

223 nificance remains unclear in pediatric lower respiratory tract infection (LRTI).

224 I), urinary tract infection (UTI), and lower respiratory tract infection (LRTI).

225 5.84 (95% CI 5.61-6.08; p < 0.001) for lower respiratory tract infection (LRTI).

226 nfirmed hospitalizations or outpatient lower respiratory tract infection (LRTI).

227 Lower respiratory tract infections (LRTIs) are a leading cause

228 Childhood lower respiratory tract infections (LRTIs) cause substantial m

229 l pathogen in hospitalized adults with lower respiratory tract infections (LRTIs).

230 growth of pathogens potentially relevant to respiratory tract infection may be triggered by changes

231 Pneumonia (n=5 [5%]) and lower respiratory tract infection (n=4 [4%]) were considered t

232 ost common serious adverse events were lower respiratory tract infection (n=7 [7%]), pneumonia (n=7 [

233 In contrast, non-CAAP lower respiratory tract infections (NA-LRI) are generally not

234 In contrast, non-CAAP lower respiratory tract infections (NA-LRIs) are generally not

235 y their child exhibited symptoms of an upper respiratory tract infection or asthma exacerbation (epis

236 /3IFNs, whereas risk for infant wheezy lower respiratory tract infections or "transient early wheeze"

237 eated with intravenous ceftriaxone for lower respiratory tract infections, oral ribaxamase reduced th

238 Eighteen (86%) patients were treated for respiratory tract infections; others were treated for bl

239 irus (CMV) antigenemia (p = 0.005) and lower respiratory tract infection (p = 0.003) and no leucopeni

240 he mean number of laboratory-confirmed upper respiratory tract infections per child was 1.05 (95% CI,

241 Subject Headings terms: "acute bronchitis," "respiratory tract infection," "pharyngitis," "rhinosinus

242 considering prevention or treatment of viral respiratory tract infections, potential targets include

243 ypically young children with upper and lower respiratory tract infection, presenting with symptoms in

244 Anemia (33.3%), upper respiratory tract infection, pyrexia, and diarrhea (26.7

245 atracheal routes to cause an upper and lower respiratory tract infection, respectively.

246 elop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial virus

247 syncytial virus (RSV) is a leading cause of respiratory tract infection (RTI) in young children.

248 Consultations for respiratory tract infection (RTI), skin or urinary tract

249 The clinical signs and symptoms of acute respiratory tract infections (RTIs) are not pathogen spe

250 urden of severe human metapneumovirus (HMPV) respiratory tract infections (RTIs) in European children

251 urden of human coronavirus (HCoV)-associated respiratory tract infections (RTIs) in hospitalized chil

252 ota stability and thereby resistance against respiratory tract infections (RTIs) over time.

253 s in the prospective cohort, 21 distinct BoV respiratory tract infections (RTIs) were observed by 1 y

254 mediator in the susceptibility to childhood respiratory tract infections (RTIs).

255 fection rates, and identify risk factors for respiratory tract infections (RTIs).

256 in uncomplicated urinary and upper and lower respiratory tract infections (RTIs).

257 ct microbiota are related to pathogenesis of respiratory tract infections (RTIs).

258 ized adults varies widely and includes upper respiratory tract infections, severe lower respiratory t

259 immunodeficiency characterized by recurrent respiratory tract infections, susceptibility to herpesvi

260 osteroids should not be used for acute lower respiratory tract infection symptoms in adults without a

261 or duration or severity of other acute lower respiratory tract infection symptoms, duration of abnorm

262 es were duration and severity of acute lower respiratory tract infection symptoms, duration of abnorm

263 Atopy and viral respiratory tract infections synergistically promote ast

264 vents in both groups were headache and upper respiratory tract infection (ten [16%] for both events i

265 respiratory tract infection to severe lower respiratory tract infection, that can lead to diffuse al

266 ted with intravenous ceftriaxone for a lower respiratory tract infection, thereby supporting continue

267 act animals demonstrated various symptoms of respiratory tract infection, they were mild, and the cal

268 ral, bacterial, or fungal pathogens, such as respiratory tract infections, this necessitates large pa

269 was medically attended RSV-associated lower respiratory tract infection through 150 days after admin

270 was hospitalization for RSV-associated lower respiratory tract infection through 150 days after admin

271 pectrum of diseases, ranging from mild upper respiratory tract infection to severe lower respiratory

272 RSV-associated, medically significant lower respiratory tract infection up to 90 days of life, and t

273 s completed daily from the onset of an upper respiratory tract infection (URTI) until asthma symptom

274 e grouped according to the presence of upper respiratory tract infection (URTI) without lower respira

275 t paediatric diarrhoea and adult acute upper respiratory tract infection (URTI), which were presented

276 There are no antivirals to treat viral upper respiratory tract infection (URTI).

277 (QoL) assessments and the incidence of upper respiratory tract infection (URTI).

278 Upper respiratory tract infections (URTIs) are important trigg

279 Chinese primary care to children with upper respiratory tract infections (URTIs), we developed an in

280 RSV-associated, medically significant lower respiratory tract infection was 1.5% in the vaccine grou

281 e of medically attended RSV-associated lower respiratory tract infection was 70.1% lower (95% confide

282 of hospitalization for RSV-associated lower respiratory tract infection was 78.4% lower (95% CI, 51.

283 One treatment-related death from a respiratory tract infection was reported in the docetaxe

284 sLTR1 signaling in the first days of a viral respiratory tract infection was sufficient to reduce acc

285 Upper respiratory tract infection was the most frequent treatm

286 for hospitalization for RSV-associated lower respiratory tract infection were 2.1% and 3.7% (vaccine

287 one focal and one systemic symptom of acute respiratory tract infection were assigned 1:1 to receive

288 Patients with severe acute respiratory tract infection were excluded.

289 enting with acute cough (for </=28 days) and respiratory tract infection were recruited to a prognost

290 Respiratory tract infections were most common and were d

291 breakthrough in the field of multimicrobial respiratory tract infections, wherein control of inflamm

292 pansion of CD8(+) T cells following an upper respiratory tract infection with a pathogenic influenza

293 had been admitted to a hospital with a lower respiratory tract infection with a pneumonia index score

294 dex was found to be a robust marker of viral respiratory tract infection with a sensitivity of 80% an

295 ponding percentages for RSV-associated lower respiratory tract infection with severe hypoxemia were 0

296 the performance of BN in infants with acute respiratory tract infections with different degrees of d

297 The outcome was hospital admission for respiratory tract infection within 30 days, collected us

298 reduced antibiotic use for non-severe acute respiratory tract infection without compromising patient

299 ibing rates when diagnostics suggested viral respiratory tract infection, without a higher rate for r

300 ibing rates when diagnostics suggested viral respiratory tract infection, without a higher rate for r